Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Celldex Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 174
- −2 vs. Q3 2024
- Shares held
- 73.7M
- +1.88M (+2.6%) vs. Q3 2024
- Total value
- $1.86B
- −$578.8M (−23.7%) vs. Q3 2024
- New holders
- 34
- 66 more added
- Sold out
- 36
- 48 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 253 | $3.16B |
| Q1 2026 | 229 | $2.31B |
| Q4 2025 | 187 | $1.99B |
| Q3 2025 | 184 | $1.83B |
| Q2 2025 | 182 | $1.48B |
| Q1 2025 | 171 | $1.34B |
| Q4 2024 | 174 | $1.86B |
| Q3 2024 | 176 | $2.44B |
| Q2 2024 | 183 | $2.58B |
| Q1 2024 | 197 | $2.91B |
| Q4 2023 | 164 | $2.42B |
| Q3 2023 | 144 | $1.39B |
| Q2 2023 | 150 | $1.70B |
| Q1 2023 | 161 | $1.78B |
| Q4 2022 | 168 | $2.17B |
| Q3 2022 | 160 | $1.39B |
| Q2 2022 | 158 | $1.30B |
| Q1 2022 | 169 | $1.69B |
| Q4 2021 | 181 | $1.79B |
| Q3 2021 | 161 | $2.33B |
| Q2 2021 | 132 | $1.19B |
| Q1 2021 | 115 | $709.5M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Celldex Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −1,210−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −139−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −95−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −92−100.0% | Sold out |
| Creative Financial Designs Inc | 0 | $0 | 0.00% | −83−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −59−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Umb Bank N A | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Householder Group Estate & Retirement Specialist, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |